Seedlabs

LightCheck: Wearable fNIRS Engagement Readout for tPBM Devices

A wearable sensor that proves a light-therapy device is actually reaching the target area of the brain.

A few-channel wearable fNIRS add-on for photobiomodulation devices that measures prefrontal oxygenation immediately before and after each light session, giving clinics and device makers an objective per-session number proving the stimulation actually engaged its target.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderNeurotechnology / medical device manufacturing — tPBM devices with wearable fNIRS verification

Concept

A business-to-business capability: a compact fNIRS headband positioned over the right prefrontal cortex, paired with 1064 nm tPBM devices, that measures prefrontal hemodynamics immediately before and after each session (during a brief 2-back working-memory task) and outputs a per-session "engagement score" — the change in oxyhemoglobin and total hemoglobin.

  • The wedge: photobiomodulation currently ships with no readout — users must take the effect on faith. This turns each session into a verifiable event: the clinic or device logs an objective number showing the light engaged the prefrontal cortex.
  • Design follows the demonstrated method: the trial acquired fNIRS before and after tPBM (not simultaneously), avoiding optical interference between the 1064 nm laser and fNIRS detectors; the product uses the same pre/post measurement window rather than promising an unproven simultaneous readout.
  • Customers: tPBM device makers (differentiation plus regulatory-grade documentation), ADHD and neuromodulation clinics (a physiological record alongside behavioral tests), and clinical-trial teams (a candidate surrogate endpoint).
  • Long game: pairing per-session oxygenation changes with behavioral results builds the responder/non-responder dataset needed to titrate dose and design the repeated-session regimens the field currently lacks.

Why now

  • The RCT demonstrated that wearable fNIRS can detect the hemodynamic signature of an effective tPBM session: active vs sham differences in prefrontal oxyhemoglobin (p = 0.011) and total hemoglobin (p = 0.038) during a 2-back task [0].
  • The oxygenation increase co-occurred with a large behavioral effect — a 51% improvement in CPT correct rejections (Cohen's d = 0.93) — making the hemodynamic change a plausible per-session indicator of response [0].
  • The intervention was acutely effective and adverse-event-free in adults with ADHD [0], while the comparative evidence base for adult ADHD interventions remains unsettled [1] — leaving space for adjuncts that can prove, session by session, that they did something.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 2 papers86

A high-utility B2B verification tool that transforms tPBM from a 'leap of faith' treatment into a data-driven clinical procedure by leveraging a demonstrated hemodynamic biomarker.

Evidence strength
5/5
The idea directly implements the methodology of the cited RCT, which specifically demonstrated a statistically significant difference in prefrontal oxyhemoglobin (p=0.011) between active and sham tPBM.
Market pull
4/5
There is strong pull from clinics and device manufacturers who need objective proof of efficacy to justify costs and improve patient retention in a field with unsettled efficacy standards.
Novelty & moat
3/5
While it builds on the 'Same-Day Impulse Session' idea, it shifts the value proposition from a behavioral report to a physiological biomarker, creating a more defensible technical moat.
Feasibility
4/5
fNIRS hardware is commercially available and the pre/post measurement protocol avoids the complex technical hurdle of simultaneous light interference.
Wedge clarity
5/5
The wedge is exceptionally sharp: a specific 'engagement score' for a specific target (right PFC) using a specific task (2-back) to validate a specific device (1064nm tPBM).
Simplicity / focus
5/5
The product is a single, focused add-on with one clear function: providing a pre/post oxygenation readout.

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Artinis Medical Systemscompany

    Dutch maker of wearable fNIRS systems (e.g., Brite); a validated tPBM-verification application gives its research-grade hardware a routine clinical use case and new customer segment.

  • Vielight Inc.company

    Pairing its 1064 nm devices with an objective per-session engagement readout would differentiate them from unverified consumer light devices and support clinical and regulatory claims.

  • NIRx Medical Technologiescompany

    fNIRS hardware vendor that could serve the same device-integration and clinic market for photobiomodulation verification.

  • The ADHD Centrecompany

    UK adult ADHD clinic that could document physiological engagement of every session, strengthening credibility with patients and future payers.

Research it builds on

  1. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis
    Edoardo Giuseppe Ostinelli, Marcel Schulze, Caroline Zangani et al. · 2024 · 79 citations
    All ideas from this paper →
  2. Transcranial photobiomodulation improves prefrontal oxygenation and impulse control in adults with ADHD: a randomized controlled trial
    Farzad Salehpour, Douglas W. Barrett, Anagh Mirji et al. · 2026 · 3 citations
    All ideas from this paper →
Leave feedback
feasibility